|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2009-8-31
|
|
pubmed:abstractText |
The antidiabetic properties of metformin are mediated through its ability to activate the AMP-activated protein kinase (AMPK). Activation of AMPK can suppress tumor formation and inhibit cell growth in addition to lowering blood glucose levels. We tested the hypothesis that metformin reduces the risk of cancer in people with type 2 diabetes.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1935-5548
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
32
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1620-5
|
|
pubmed:dateRevised |
2010-9-2
|
|
pubmed:meshHeading |
pubmed-meshheading:19564453-Adult,
pubmed-meshheading:19564453-Aged,
pubmed-meshheading:19564453-Aged, 80 and over,
pubmed-meshheading:19564453-Cohort Studies,
pubmed-meshheading:19564453-Diabetes Mellitus, Type 2,
pubmed-meshheading:19564453-Female,
pubmed-meshheading:19564453-Humans,
pubmed-meshheading:19564453-Hypoglycemic Agents,
pubmed-meshheading:19564453-Male,
pubmed-meshheading:19564453-Metformin,
pubmed-meshheading:19564453-Middle Aged,
pubmed-meshheading:19564453-Neoplasms,
pubmed-meshheading:19564453-Proportional Hazards Models
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes.
|
|
pubmed:affiliation |
Division of Clinical and Population Sciences and Education, University of Dundee, Dundee, UK.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
